Stem Cell Therapy for Heart Disease & Vascular Conditions

Cardiovascular conditions include a range of disorders affecting the heart and blood vessels, from coronary artery disease and ischaemic heart disease to peripheral vascular conditions and microvascular dysfunction. These conditions share underlying mechanisms including atherosclerosis (plaque buildup in arteries), endothelial dysfunction (impaired blood vessel lining function), and cardiac tissue damage from ischaemic events such as heart attacks. When heart muscle is damaged by a heart attack, the body replaces functional cardiac tissue with scar tissue (fibrosis) that cannot contract or conduct electrical signals, leading to reduced cardiac output, heart failure symptoms, and arrhythmia risk. Peripheral vascular disease affects blood flow to the extremities, causing pain, impaired healing, and in severe cases tissue loss. Microvascular dysfunction, often underdiagnosed, affects the smallest blood vessels and can cause symptoms even when larger coronary arteries appear normal on angiography. At Boston Health Longevity, we assess cardiovascular patients with a focus on understanding the specific nature and extent of their vascular or cardiac damage before recommending regenerative protocols.

Cardiovascular applications of stem cell therapy have been studied extensively in both preclinical models and clinical trials. The key biological mechanisms through which MSCs may support cardiovascular health include promoting angiogenesis (stimulating the growth of new blood vessels to improve blood supply to damaged tissue), reducing cardiac fibrosis (limiting scar tissue formation and potentially modulating existing fibrotic tissue), exerting anti-inflammatory effects on damaged cardiac tissue, and supporting the survival and function of existing cardiomyocytes through paracrine signalling. Clinical trials in post-heart attack patients have reported improvements in left ventricular ejection fraction, reduced infarct size, and improved exercise tolerance. Research into peripheral vascular disease has examined the potential of MSCs to improve blood flow to ischaemic limbs, with some studies reporting improved ankle-brachial index measurements and wound healing. The paracrine hypothesis, which suggests that MSCs exert their primary benefits through the release of bioactive molecules rather than direct tissue replacement, has become the dominant framework for understanding cardiovascular stem cell therapy.

Our cardiovascular protocols address the key biological processes involved in cardiac and vascular repair, including angiogenesis promotion, endothelial progenitor cell mobilisation, cardiac fibrosis modulation, cardiomyocyte paracrine support, microvascular perfusion enhancement, and inflammatory cytokine regulation in ischaemic tissue. These pathways represent the primary mechanisms through which umbilical cord-derived mesenchymal stem cells may support cardiovascular tissue recovery.

Cardiovascular patients who explore stem cell therapy typically have conditions where conventional treatment has reached its practical limits. Post-heart attack patients who have completed rehabilitation but still experience reduced cardiac function and exercise intolerance may seek approaches that could support further recovery beyond what conventional rehab achieves. Patients with heart failure who are not candidates for transplantation or mechanical circulatory support represent another group seeking options. Those with peripheral vascular disease who face potential amputation despite optimal medical management may explore regenerative approaches as a means of improving blood flow to threatened limbs. Patients with microvascular dysfunction, often frustrating to treat with conventional approaches, may seek MSC therapy for its potential to improve small vessel function. The common motivation across cardiovascular patients is the desire to address the underlying tissue damage and vascular impairment that medications alone cannot reverse.